Watchlist

Watchlist
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative womens healthcare company, today announced that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 in San Francisco. Chief Executive Officer Robert G. Finizio and Chief Clinica…
Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides Update
Analysis of top Seeking Alpha coverage: Progenics Today we will discuss the latest update from Progenics Pharmaceuticals ( PGNX ), which sparked a rally in pre-market trading on Friday . Progenics announced that the FDA has accepted for review its New Drug Application (NDA) for Azed…
Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial
Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year…
After Hours Gainers / Losers
Top gainers: TXMD +4.2% . QIWI +2.8% . HL +2.2% . CRNT +1.5% . MYL +1.3% . More news on: TherapeuticsMD, QIWI plc, Hecla Mining Co., Stocks on the move, Read more …
TherapeuticsMD submits NDA for TX-001HR
TherapeuticsMD (NYSEMKT: TXMD ) announces submitting a New Drug Application for TX-001HR for moderate-to-severe vasomotor symptoms due to menopause. More news on: TherapeuticsMD, Healthcare stocks news, Stocks on the move, Read more …
TherapeuticsMD Announces Submission of New Drug Application for TX-001HR
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative womens healthcare company, announced today that it has submitted the New Drug Application (NDA) for TX-001HR, the companys investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, or…
TherapeuticsMD: Class 2 Re-Submission Is Not The End Of The World
Don't lose sight of the forest for the trees. Overview On December 19, 2017, TherapeuticsMD (TXMD) announced that the FDA has labeled the submission as Class 2 and will announce its decision on approval by May 29, 2018. The impact of Class 2 may not be as negative as what many have perce…
Stocks to watch next week
Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: Wal-Mart Stores, Inc., Target Corporation, Amazon.com, Inc., Consumer stocks news, Tech stocks news, Financial stocks ne…
Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval
Content Analysis of coverage: AEZS Stocks in the news: Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Catalyst Rundown Analysis of top Seeking Alpha coverage: AEterna Zentaris Today we will foc…
Premarket Losers as of 9:05 am
ACST -27% on announcing planned public offering. More news on: Acasti Pharma, Inc., ChinaCache International, Stitch Fix, Inc., Stocks on the move, Read more …
FDA accepts TherapeuticsMD's marketing application for TX-004HR, action date May 29, 2018
The FDA accepts for review TherapeuticsMD's (NYSEMKT: TXMD ) resubmitted marketing application seeking approval for TX-004HR (estradiol vaginal softgel capsule) for the treatment of women with moderate-to-severe vaginal pain during intercourse (dyspareunia). The agency's action date is May…
TherapeuticsMD, Inc. (TXMD)